Prevention and early detection of vascular complications of diabetes by Marshall SM & Flyvbjerg A
Clinical review
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Sally M Marshall, Allan Flyvbjerg
Diabetes reduces life expectancy by five to 10 years.
Premature cardiovascular disease is the most common
cause of morbidity and mortality, but the microvascular
complications specific to diabetes (box 1) are also con-
tributory factors. Diabetes is the most common reason
for renal replacement therapy worldwide, the most
common cause of blindness in the under 65s, and the
most common cause of non-traumatic amputation.
With our current knowledge, most of these devastating
events could be prevented or delayed, or their impact
minimised. This review focuses on the prevention,
early detection, and initial management of the vascular
complications of diabetes in adults.
Why are the complications of diabetes
important?
Complications are common and the cost to the
individual and society is enormous. The onset of com-
plications reduces quality of life, particularly when
both microvascular and macrovascular disease are pre-
sent.w1 The CODE-2 study gathered data on 7000 peo-
ple with type 2 diabetes from eight European studies—
72% had at least one complication and 24% had both
(microvascular and macrovascular) complications.w2
Over six months, 13% of the patients were admitted to
hospital for a mean of 23 days. The estimated average
yearly cost per patient was €2834 (£1934, $3585); 55%
of this cost was attributable to hospital admissions and
only 7% to the cost of insulin and oral drugs for lower-
ing glucose.1
Who develops complications?
The risk of developing complications is variable (table
1). For nephropathy, in particular, a strong but
unknown genetic influence exists. The duration of dia-
betes, glycaemic control, and hypertension are the
strongest risk factors for microvascular disease;
smoking, blood pressure, lipids, and albuminuria are
the strongest risk factors for macrovascular disease.
Macrovascular disease
Excess mortality from cardiovascular disease is seen in
all age groups, particularly in young people with type 1
diabetes (box 2), and is exacerbated by social
deprivation (table ).w3 Premenopausal women with dia-
betes lose their protection against macrovascular
disease (fig A on bmj.com).2 w4 w5 In type 2 diabetes, the
risk of myocardial infarction and stroke is two to five
times higher than in the general population.
Retinopathy
The World Health Organization estimates that diabetic
retinopathy is the cause of blindness in 5% of blind peo-
ple worldwide.3 Almost everyone with diabetes has some
degree of retinopathy after 20 years (see appendix on
bmj.com for the grading of diabetic retinopathy), but
only 20-50% of patients develop sight threatening
disease. In some centres the cumulative incidence of
sight threatening retinopathy is falling.4 w6 w7
Nephropathy
About half of patients with diabetes develop microalbu-
minuria at some point. Approximately one third will
progress to proteinuria, one third will remain micro-
albuminuric, and one third will revert to normal
albumin excretion (fig 1).w8 Microalbuminuria and
Summary points
Patients with diabetes have an average reduction
in life expectancy of five to 10 years, mainly
because of premature cardiovascular disease
The microvascular complications specific to
diabetes (retinopathy, nephropathy, neuropathy)
also contribute to premature mortality and
morbidity
The risk of vascular complications can be greatly
reduced by tight control of glucose and blood
pressure and by aggressive management of
cardiovascular risk factors
Early detection of complications, by systematic
annual screening, allows prompt intervention that
may prevent or delay the emergence of end stage
disease
A multifactorial approach to tightening the
management of risk factors reduces the
progression of microvascular and macrovascular
complications
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proteinuria are more common in ethnic minorities
worldwide.w9 w10 Once proteinuria is present, progression
to end stage renal disease is inevitable. From 20% to
50% of patients who start renal replacement therapy
have diabetes.5 w11 The rapid increase in the numbers of
patients with diabetes requiring renal replacement in
Europe in recent years is due mainly to the rise in the
number of patients with type 2 diabetes (fig B on
bmj.com).6
Neuropathy
Patients with diabetes have a 30-50% lifetime risk of
developing chronic peripheral neuropathy (box 3), and
10-20% of patients develop severe symptoms.7 w12 w13
Peripheral neuropathy contributes to foot ulceration
and amputation of lower limbs.8 Erectile dysfunction
occurs in up to 50% of men over 50 years, compared
with 15-20% of men without diabetes. Other neuropa-
thies are rare but have a major impact on quality of life
and life expectancy.
Pathophysiology
Both the metabolic and haemodynamic abnormalities
of diabetes contribute to the development of complica-
tions. Intracellular hyperglycaemia develops in cells
that cannot downregulate the uptake of glucose. This
stimulates biochemical and haemodynamic pathways
(fig 2). Signalling molecules and growth factors are
activated, with consequent tissue damage.9 Genetic fac-
tors and external “accelerators” also contribute. A
mechanism that links the activation of these pathways
to the overproduction of superoxide by the mitochon-
drial electron transport chain has been suggested.10
Microvascular complications are strongly associated
with cardiovascular disease. A familial or genetic process
may influence the development of both cardiovascular
disease and microvascular pathology.w14-w16
How do I prevent complications?
Box 4 lists the main strategies to prevent the complica-
tions of diabetes.
Glucose control
The diabetes control and complications trial (DCCT)
in type 1 diabetes and the UK prospective diabetes
study (UKPDS) in type 2 diabetes showed that the
lower the glycated haemoglobin achieved the lower the
risk of microvascular complications.11 12 During the
eight year open follow-up of the DCCT cohort,
glycated haemoglobin values were similar in patients
who had previously been managed intensively or con-
ventionally.13 14 w17 Despite this, patients who had previ-
ously been in the intensively managed group were less
likely to have microvascular complications (fig 3). Thus,
a period of good glycaemic control reduces the risk of
complications for longer than the duration of tight
control, a phenomenon known as metabolic memory.
The association between glucose control and
cardiovascular disease is less strong but is still
important. UKPDS found a 14% reduction in the risk
of myocardial infarction for each 1% reduction in gly-
Box 1: Long term vascular complications of
diabetes
Microvascular complications
• Retinopathy
• Nephropathy
• Neuropathy
Macrovascular complications
• Cerebrovascular disease
• Ischaemic heart disease
• Peripheral arterial disease
Table 1 Risk factors and markers for the development of complications of diabetes
Factors Microvascular disease Macrovascular disease
Non-modifiable
Genetic (susceptibility or protective ) ++ ++
Ethnic origin + +
Duration of diabetes ++ +
Modifiable or potentially modifiable
Glycaemic control ++ +
Blood pressure ++ ++
Blood lipids + ++
Smoking + ++
Body mass index or waist to hip ratio + +
Other microvascular complications + +
Cardiovascular complications + +
Social deprivation + +
Novel risk markers
Markers of inflammation (such as C reactive protein) + +
Markers of endothelial dysfunction (such as von
Willebrand factor)
+ +
+=Moderate risk factor or marker; ++=strong risk factor or marker.
Sources and selection criteria
• We searched PubMed with the keywords “diabetic
complications”, “retinopathy”, “diabetic nephropathy”,
“microalbuminuria”, “diabetic foot”, “peripheral
neuropathy”, “cardiovascular disease”, “ischaemic heart
disease”, “peripheral arterial disease”, and
“cerebrovascular disease”. We gave preference to
original articles published within the past three years
and to reviews in journals with a high impact factor
(rate of citation)
• We searched the Cochrane database of systematic
reviews; Cochrane database of abstracts and reviews of
effectiveness; and Cochrane central registry of
controlled trials
• We searched personal archives of references
Box 2: Macrovascular disease in diabetes
• Macrovascular disease is the main cause of death in
type 1 and type 2 diabetes
• Excess mortality is seen in all age groups, especially
the young
• Premenopausal women lose their protection against
macrovascular disease
• Disease is diffuse, distal, and affects many vessels
• Reocclusion and reinfarction rates are higher after
thrombolysis
• Restenosis rates are higher after angioplasty,
although drug eluting stenting may help
• Five year survival after coronary artery bypass
grafting is lower than in non-diabetic patients
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cated haemoglobin.w18 In the long term follow-up of
DCCT, the risk of a cardiovascular event was 42% lower
in the intensively managed group (fig C on bmj.com).15
Blood pressure
In UKPDS, tight control of blood pressure (144/82 v
154/87 mm Hg) reduced the incidence of a microvas-
cular event by 37%.16 A reduction in systolic blood
pressure of 10 mm Hg was associated with a 13%
reduction in risk for a microvascular event and an 11%
reduction for myocardial infarction.w19 Other studies
have shown that the reduction in relative risk is at least
as great in the diabetic population as in the
non-diabetic population, so that the absolute benefits
of a reduction in blood pressure are greater.17 18
The choice of initial antihypertensive drug is less
important than reducing blood pressure. Tight targets
( < 130/80 mmHg) are difficult to reach and require at
least three antihypertensive drugs. Drugs that are taken
once daily and that have good 24 hour cover should be
used.
A Cochrane review suggests that angiotensin
converting enzyme inhibitors are the best drugs to
prevent microalbuminuria and nephropathy.19 w20 A
recent meta-analysis that did not support this
conclusion has been criticised for many reasons.w21
Lipids
Two placebo controlled trials have shown that
treatment with statins reduces the risk of a major
cardiovascular event by 37% in patients with type 2
diabetes without clinically apparent cardiovascular dis-
ease.20 21 The reduction in relative risk is as great in the
diabetic population as in the non-diabetic population,
so that the absolute benefit is greater.22 Thus, all
patients with diabetes aged 40 years or more should be
offered statins. Younger patients have a high lifetime
risk of cardiovascular disease even though their 10 year
risk is relatively low. Statins should be offered to those
at particularly high risk (box 4).
When fibrates should be prescribed is unclear. In a
recent large, randomised, controlled trial, fenofibrate
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Microalbuminuria
50%30-50%
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Fig 1 Development of nephropathy
Box 3: Neuropathies in diabetes
Peripheral neuropathies
• Distal symmetric sensorimotor neuropathy
• Femoral neuropathy (amyotrophy)
• Mononeuropathies (ocular or truncal)
• Pressure palsies (median, ulnar, or lateral popliteal)
Autonomic neuropathy
• Postural hypotension
• Bladder dysfunction
• Gastric paresis
• Constipation or diarrhoea, or both
• Gustatory sweating (on the forehead, face, scalp, and
neck after eating)
• Erectile dysfunction
Hyperglycaemia
Genetic
influences
Independent accelerators, such
as hypertension, lipids, smoking
Diabetic vascular disease
Metabolic factors
  Glucose toxicity
  Glycation
  Polyol pathway
  Hexosamine pathway
Haemodynamic factors
  Angiotensin II/renin
    angiotenin system
  Endothelium
  Nitric oxide
Growth factors and
  cytokines
  Transforming growth
  factor β, vascular
  endothelial growth
  factor, angiotensin II,
  connective tissue
  growth factor, growth
  hormone, and insulin-
  like growth factor I
Intracellular factors
  Diacylglycerol-protein
  kinase, mitogen
  activated protein
  kinase, and nuclear
  factor κ B
Fig 2 Metabolic pathways that contribute to vascular complications
of diabetes
Box 4: Preventing complications
Glucose control
• Glycated haemoglobin should be as low as possible
(but avoid undue hypoglycaemia)—aim for < 7.0% if
the patient is on insulin or < 6.5% if not on insulin
Blood pressure
Blood pressure should be as low as possible (avoiding
symptoms of postural hypotension)—aim for < 130/80
mm Hg or < 125/75 mm Hg if proteinuria is present,
if the glomerular filtration is < 60 ml/min/1.73 m2, or
if the patient has cardiovascular disease
Lipids
• Statins should be prescribed for patients over 40
• Statins should be prescribed for patients under 40
who have microvascular or macrovascular
complications, hypertension, metabolic syndrome, or a
strong family history of cardiovascular disease
• Total cholesterol should be < 4.5 mmol/litre
• Low density lipoprotein-cholesterol should be < 2.5
mmol/litre
• Fibrates should be prescribed if triglycerides are
> 2.3 mmol/litre and low density
lipoprotein-cholesterol values are < 2.5 mmol/litre
Aspirin
• Aspirin should be prescribed for all patients over 40
Smoking
• Patients should be encouraged to stop smoking
Lifestyle
• Patients should be encouraged to lose weight if
necessary, exercise, and eat healthily
Clinical review
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did not reduce the risk of primary coronary events in
type 2 diabetes.23 Despite the lack of robust evidence,
however, once low density lipoprotein-cholesterol and
control of blood glucose are optimal, clinicians should
consider adding a fibrate to statin therapy if
triglycerides are still greater than > 2.3 mmol/litre.
Smoking
It is essential that patients stop smoking to reduce the
risk of cardiovascular disease and probably the risk of
microvascular complications.
Aspirin
Although no studies have been performed on primary
prevention of cardiovascular disease in diabetes, low
dose aspirin is usually recommended, even in the
absence of overt cardiovascular disease.
How do I detect and screen for
complications?
Complications must be diagnosed early—prompt
intervention may prevent or delay the emergence of
end stage disease such as blindness, the need for renal
replacement therapy, or amputation. A systematic,
structured screening programme, run annually, is most
cost effective as a “one stop” package.
Macrovascular disease
Screening for macrovascular disease rests on symp-
toms of angina or claudication and with a low
threshold for investigation. Routine exercise tolerance
testing or stress echocardiography are not recom-
mended. A 12 lead resting electrocardiogram has low
sensitivity and specificity, although it does provide a
useful baseline.
Retinopathy
Corrected visual acuity should be measured and retin-
opathy assessed. Retinal photography, usually through
dilated pupils and performed and interpreted by
trained healthcare professionals, is the preferred
method. Sensitivity and specificity must be acceptable,
there must be an ongoing quality assurance pro-
gramme, and the number of images that cannot be
graded must be low.w22 Screening with static or
“mobile” cameras can be performed in the community;
the retinal images are read on site or at a distant centre.
Nephropathy
Urine albumin and serum creatinine should be
measured annually (fig 4). Positive urine samples
should be repeated at least twice. Trends in albumin
excretion with time are important. An estimated
glomerular filtration rate is a better reflection of
glomerular filtration than serum creatinine. Laborato-
ries in the United Kingdom now do such estimations
automatically, and web based calculators are available.
Table 2 shows the agreed classification of renal disease
based on estimated glomerular filtration rate.
Neuropathy and peripheral arterial disease
Box 5 shows what needs to be done to identify the four
classic risk factors for developing diabetic foot
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Fig 3 Prevalence of complications at open follow-up of patients who
completed the diabetes control and complications trial. Prevalence of
progression at *four years and †eight years
Table 2 Classification of chronic kidney disease
Stage Description
1 Normal glomerular filtration rate (>90 ml/min/1.73 m
2) with other
evidence of kidney disease*
2 Mild impairment: glomerular filtration rate 60-90 ml/min/1.73 m2 with
other evidence of kidney disease*
3 Moderate impairment: glomerular filtration rate 30-59 ml/min/1.73 m2
4 Severe impairment: glomerular filtration rate 15-29 ml/min/1.73 m2
5 Established renal failure: glomerular filtration rate <15 ml/min/1.73
m2 or on dialysis
*Other evidence of kidney disease: microalbuminuria, persistent proteinuria,
persistent haematuria after exclusion of all other causes, structural
abnormalities of the kidney on ultrasound, or biopsy confirmed glomerular
nephritis.
Box 5: Screening for peripheral neuropathy
and peripheral arterial disease
• Inquire about symptoms of peripheral neuropathy
and peripheral vascular disease
• Ask about previous foot ulceration or amputation
• Ask about physical or visual difficulty in self
management of foot care
• Inspect feet for evidence of deformity, neuropathy,
ischaemia, infection
• Detect neuropathy with a 10 g monofilament or 128
Hz tuning fork or biosthesiometer. Use non-traumatic
pin prick testing
• Assess arterial circulation by measuring dorsalis
pedis and posterior tibial foot pulses; measure
Doppler ankle: brachial pressure ratio if available
Annually, if glucose control is stable
Serum creatinine, calculate estimated glomerular filtration rate
Early morning urine sample. Dipstick for proteinuria
≥2++ <2++
Yes, repeat twice
within three months No, repeat annually
Urinary protein:creatinine ratio Urinary albumin:creatinine ratio
2.5-30 mg/mmol (men)
3.5-30 mg/mmol (women)
Fig 4 Screening for diabetic nephropathy
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problems (deformity, neuropathy, ischaemia, and
infection).24 Questions should be asked about erectile
function. Tests of autonomic function are not
performed routinely.
How do I manage early complications?
General
Tight control of blood glucose and blood pressure
reduces the risk of progression of background diabetic
retinopathy to sight threatening disease and the
progression of neuropathy.11 12 16 The effect of glucose
control on progression of nephropathy is less certain.
Blood pressure and lipid control are extremely impor-
tant.
Cardiovascular disease
Most importantly, all patients with symptoms that
might reflect vascular disease, particularly ischaemic
heart disease, should be investigated. The absolute
benefits of treatment with statins in secondary preven-
tion of vascular disease are greater in people with dia-
betes.22
Retinopathy
Frequent retinal examination may be required, with
referral to the ophthalmology department when sight
threatening disease is apparent (table 3).
Nephropathy
All patients should be prescribed a long acting, once
daily angiotensin converting enzyme inhibitor or angi-
otensin receptor blocker titrated up to the maximum
recommended or tolerated dose.w23-w26 Additional
antihypertensives should be used to achieve tight con-
trol of blood pressure. A target of 125/75 mm Hg is
recommended for patients with proteinuria or an esti-
mated glomerular filtration rate less than 60 ml/min/
1.73 m2, although these guidelines are not evidence
based. Combining an angiotensin converting enzyme
inhibitor with an angiotensin receptor blocker or add-
ing an aldosterone antagonist further reduces urine
albumin excretion and blood pressure in the short
term.w27-w29 However, long term benefits are unclear.
Box 6 lists the indications for referral to the
nephrology department.
Neuropathy and peripheral arterial disease
Patients whose feet have a high risk of ulceration or
gangrene need support and education about foot care;
they also need to be given prophylactic foot care and
special footwear.24 These measures can reduce
amputation rates by 30-50%.w30 w31 Early referral of
patients with ulcers (and those who have had ulcers in
the past) to a specialist multidisciplinary team is essen-
tial.
Support and counselling should be available for
men with erectile dysfunction. Investigations to
exclude other causes (measurement of prolactin,
follicle stimulating hormone, luteinising hormone, tes-
tosterone, and sex hormone binding globulin) may be
necessary. Oral phosphodiesterase type 5 inhibitors
are effective in about 60% of men with diabetes, less
than in the non-diabetic population. Alternatives
include sublingual apomorphine, intraurethral drugs,
intracavernosal drugs, vacuum devices, and penile
prostheses.
The importance of multifactorial care
A small randomised controlled trial of patients with
type 2 diabetes, microalbuminuria, and hypertension
showed the importance of a structured, protocol
driven, multifactorial approach to managing the com-
plications of diabetes.25 The intensively managed
group received lifestyle advice, aspirin, and angiotensin
converting enzyme inhibitors, with tight targets for
glucose, blood pressure, and lipids in a specialist
setting. The conventionally managed group received
usual structured care in a primary care setting. Over
eight years, the risks of progression of microvascular
and macrovascular disease were reduced by 40-60% in
the intensively managed group (table 4).
How well are we doing?
Targets are not being met and drugs are not being pre-
scribed appropriately in most patients with diabetes
worldwide.w32 w33 Screening programmes for retinopa-
thy and nephropathy are patchy or non-existent.w34 w35
In the UK, the uptake for retinal screening was 57.3%
in 2005 (www.yhpho.org.uk). Patients find it difficult to
comply with lifestyle advice, attendance for screening,
and drugs,w36 w37 and those with most difficulty have
worse outcomes.w38 w39
Table 3 Urgency of referring patients with diabetic retinopathy to
the ophthalmology department
Problem
Time within which patient should
be seen by ophthalmologist
Sudden loss of vision Same day
Retinal detachment Same day
New vessel formation 2 weeks
Vitreous or preretinal haemorrhage 2 weeks
Rubeosis iridis 2 weeks
Hard exudates within 1 disc diameter of
fovea
12 weeks
Clinically important macular oedema 12 weeks
Unexplained retinal findings 12 weeks
Severe non-proliferative disease 12 weeks
Adapted from National Screening Programme for Diabetic Retinopathy
workbook, version 3 (www.nscretinopathy.org.uk).
Box 6: Indications for referring patients to the
nephrology department
• The glomerular filtration rate is < 45 ml/min/1.73
m2 (if possible, refer when < 60 ml/min/1.73 m2) or
serum creatinine is > 150 mol/litre
• The estimated glomerular filtration rate falls by
more than 20% each year
• Presence of nephrotic syndrome
• The diagnosis is unclear
• Blood pressure is uncontrolled
• Haemoglobin is < 100 g/litre and other causes have
been excluded
• Presence of abnormalities in bone chemistry
Table 4 Benefits of multifactorial intervention25
Complication Hazard ratio (95% confidence interval)
Cardiovascular disease 0.47 (0.24 to 0.73)
Nephropathy 0.39 (0.17 to 0.87)
Retinopathy 0.42 (0.21 to 0.86)
Autonomic neuropathy 0.37 (0.18 to 0.79)
Clinical review
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How can we improve?
Many changes are needed to prevent the complica-
tions of diabetes and minimise their impact. Under the
auspices of the Austrian presidency, the European
Union has developed a national plan of action for care
in diabetes (www.diabetesconference.at), and such a
plan has already been enacted in Finland
(www.diabetes.fi/english/programme).
The most successful interventions include many
components of care contained within the chronic care
model,w40 w41 as described recently for foot care26:
x Organisation of care
x Clinical information systems
x Support for clinical decisions
x Delivery of care
x Support for self management.26
Many examples of novel ways of improving
outcomes exist. In the UK, the “payment by results”
scheme of the primary care quality outcomes
framework has resulted in many practices reaching the
specified targets (www.icservices.nhs.uk). Overall, prac-
tices attained 93.2% of the total available points for
diabetes. Appreciable benefits are likely to be seen as
the targets for glycated haemoglobin, lipids, and blood
pressure values are tightened.
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